EC
RNAM

EntryPoint Capital’s Avidity Biosciences RNAM Stock Holding History

EntryPoint Capital’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,968
Closed -$80.4K – 1051
2024
Q2 		$80.4K Sell
1,968
-2,360
-55% -$67.7K 0.12% 399
2024
Q1 		$110K Sell
4,328
-7,086
-62% -$111K 0.1% 362
2023
Q4 		$103K Buy
+11,414
New +$76.3K 0.1% 370

Other funds holding RNAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EntryPoint Capital's RNAM Position: Q3 2024 in Review

EntryPoint Capital sold out of Avidity Biosciences (RNAM) in Q3 2024, closing a stake of 1,968 shares — an estimated $80.4K sold.

EntryPoint Capital first reported a position in RNAM in Q4 2023 and held it in 3 quarters. The position peaked at $110K in Q1 2024. 245 funds tracked by Wall St. Rank hold RNAM as of Q3 2024.

  • EntryPoint Capital reported no remaining Avidity Biosciences position as of Q3 2024 after selling out during the quarter.
  • EntryPoint Capital sold 1,968 Avidity Biosciences shares in Q3 2024, an estimated $80.4K.
  • EntryPoint Capital first reported a position in Avidity Biosciences in Q4 2023 and held it in 3 quarters.
  • EntryPoint Capital's Avidity Biosciences position peaked at $110K in Q1 2024.
  • 245 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.